Fund BasicsSee More
- Fund Family IndexIQ
- Assets Under Management 740,096,000
- Shares Outstanding, K 22,400
- 60-Month Beta 0.17
|Period||Period Low||Period High||Performance|
| || |
-0.06 (-0.19%)since 08/20/21
| || |
-0.58 (-1.74%)since 06/21/21
| || |
+0.28 (+0.85%)since 09/21/20
With COVID-19 vaccination taking momentum, the outlook for large U.S. companies' corporate actions is looking bright.
On Feb 27, the United States sanctioned Johnson & Johnson's COVID-19 vaccine for emergency use, giving the nation a third vaccine to fight the outbreak, after BioNTech/Pfizer and Moderna.
Though the counting process for the U.S. election outcome is still on, the prospect of a Joe Biden presidency marked by a divided Congress is rife.
This M&A ETF hits a new 52-week high. Are more gains in store for this ETF?
It was a great Q3 for mergers and acquisitions (M&A) that were on hold amid the peak of coronavirus-led lockdowns.
The October-December period will revolve around the events like holiday season, presidential election, vaccine trials and stimulus talks.
Mergers and acquisitions had a great third quarter as deal activities that were on hold amid the peak of coronavirus-led lockdowns opened the floodgates.
After tumbling to the lowest level in more than a decade in the second quarter, global M&A activity gathered steam in September following the flurry of latest deal activities.
Amid coronavirus-related uncertainties, Intel and Nvidia announced two acquisitions that can facilitated their existing portfolio.
This merger and acquisition ETF hits a new 52-week high. Are more gains in store for this ETF?
|3rd Resistance Point||33.56|
|2nd Resistance Point||33.28|
|1st Resistance Point||33.14|
|1st Support Level||32.72|
|2nd Support Level||32.44|
|3rd Support Level||32.30|